Antagonistic role of GSK3 isoforms in glioma survival

Area of Science:

• Neuro-oncology
• Molecular Biology
• Cancer Genetics

Background:

• Glycogen Synthase Kinase-3 (GSK3) has two isoforms, GSK3 alpha and GSK3 beta, with distinct roles in cellular processes.
• Imbalances in GSK3 isoform expression are implicated in oncogenesis, particularly in gliomas where their functions differ from other cancers.

Purpose of the Study:

• To investigate the specific roles of GSK3 alpha and GSK3 beta isoforms in glioma development.
• To elucidate the regulatory mechanisms involving GSK3 isoforms, hnRNPA1, and alternative splicing in gliomas.

Main Methods:

• Utilized GSK3 alpha knockdown and GSK3 beta overexpression models in U87 glioma cells.
• Employed siRNA and gene overexpression techniques to study hnRNPA1-dependent signaling pathways.
• Analyzed the expression of key proteins such as c-Myc, hnRNPA1, phospho-ERK1/2, and Cyclin D1.

Main Results:

• GSK3 isoforms inversely regulate hnRNPA1 expression, impacting alternative splicing of genes like BIN1, RON, Mcl1, and PKM in gliomas.
• GSK3 alpha knockdown mimicked GSK3 beta overexpression effects, leading to elevated c-Myc, hnRNPA1, phospho-ERK1/2, and Cyclin D1, promoting cell survival.
• hnRNPA1-dependent survival signaling pathways were confirmed through siRNA and gene overexpression studies.

Conclusions:

• The study empirically supports a dual role for GSK3 isoforms in glioma, with GSK3 beta promoting oncogenesis and GSK3 alpha potentially acting as a tumor suppressor.
• Inhibition of GSK3 beta combined with restoration of GSK3 alpha presents a potential therapeutic strategy for targeting gliomas.